Drug intelligence / Profile preview

KAL_002

Development stage: Preclinical
Lead developer: Sichuan Yanyang Biotechnology
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

KAL_002 is an innovative live biotherapeutic product (LBP) being developed by Sichuan Yanyang Biotechnology for the treatment of radiation enteritis and chemotherapy-induced diarrhea. As a microbiome-based therapy, it consists of specific live anaerobic bacteria designed to colonize the gastrointestinal tract and restore microbial balance following damage from oncological treatments. The mechanism involves the modulation of the gut microbiota to suppress inflammatory responses and promote the repair of the intestinal mucosal barrier. Currently in the IND-enabling phase, KAL_002 represents a novel approach to managing the gastrointestinal toxicities associated with cancer therapy by leveraging the therapeutic potential of the human microbiome.

Beyond the preview

Go deeper on KAL_002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAL_002.

Explore the full profile